Simon Moroney
Chairman chez BIOTALYS NV
Fortune : 581 238 $ au 31/03/2024
Profil
Simon E.
Moroney was the founder of MorphoSys AG, a company founded in 1992, where he held the title of Chief Executive Officer from 1992 to 2019.
He is currently Vice Chairman at Novartis AG since 2020 and Chairman at Biotalys NV since 2021.
In his former positions, he served as Director-Supervisory Board at ProtAffin Biotechnologie AG from 2009 to 2011, and as President at the Government of Germany.
He also worked as a Research Associate at the University of Cambridge from 1991 to 1992, as an Assistant Professor at the University of British Columbia, as an Associate in the Chemistry Department at the Swiss Federal Institute of Technology from 1986 to 1989, and as an Associate at Harvard Medical School from 1984 to 1986.
Dr. Moroney obtained a doctorate degree from the University of Oxford in 1984 and a graduate degree from Waikato University in 1981.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NOVARTIS AG
0,00% | 31/12/2023 | 5 992 ( 0,00% ) | 581 238 $ | 31/03/2024 |
Postes actifs de Simon Moroney
| Sociétés | Poste | Début |
|---|---|---|
| NOVARTIS AG | Director/Board Member | 28/02/2020 |
| BIOTALYS NV | Chairman | 01/04/2021 |
Anciens postes connus de Simon Moroney
| Sociétés | Poste | Fin |
|---|---|---|
| MORPHOSYS AG | Chief Executive Officer | 01/09/2019 |
ProtAffin Biotechnologie AG
 ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Director/Board Member | 17/02/2014 |
| University of Cambridge | Corporate Officer/Principal | 01/01/1992 |
| Swiss Federal Institute of Technology | Corporate Officer/Principal | 01/01/1989 |
| Harvard Medical School | Corporate Officer/Principal | 01/01/1986 |
Formation de Simon Moroney
| University of Oxford | Doctorate Degree |
| Waikato University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| NOVARTIS AG | Health Technology |
| MORPHOSYS AG | Health Technology |
| BIOTALYS NV | Process Industries |
| Entreprise privées | 2 |
|---|---|
| Government of Germany | Government |
ProtAffin Biotechnologie AG
ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Health Technology |
